688062.SHG Mabwell (Shanghai) Bioscience Co. Ltd. A
- Market cap
- CNY 9.62B
- P/E
- -
- P/B
- 10.44x
- ROE
- -119.5%
- Dividend yield
- 0.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688062.SHG undervalued?
Graham numberThe Graham number of Mabwell (Shanghai) Bioscience Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mabwell (Shanghai) Bioscience Co. Ltd. A fundamental analysis
No fundamental analysis for Mabwell (Shanghai) Bioscience Co. Ltd. A yet.
Mabwell (Shanghai) Bioscience Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mabwell (Shanghai) Bioscience Co. Ltd. A
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injecti…
Full company profileMabwell (Shanghai) Bioscience Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mabwell (Shanghai) Bioscience Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.60M | 37.4M | 29.4M | 5.30M | 16.2M | 27.7M | 128M | 200M | 663M | 625M |
| Gross Profit | 2.92M | 11.3M | 12.0M | -99.3K | 11.0M | 25.7M | 121M | 165M | 387M | 472M |
| Operating Income | -106M | -237M | -928M | -644M | -773M | -958M | -1.05B | -1.04B | -956M | -878M |
| EBITDA | -91.1M | -215M | -886M | -586M | -704M | -883M | -968M | -893M | -860M | -928M |
| Net Income | -103M | -225M | -928M | -643M | -770M | -955M | -1.05B | -1.04B | -970M | -1.04B |
| EPS | -0.36 | -0.79 | -3.17 | -2.26 | -2.57 | -2.44 | -2.64 | -2.61 | -2.43 | -2.34 |
| Balance Sheet | ||||||||||
| Total Assets | 636M | 892M | 1.07B | 1.64B | 1.60B | 4.62B | 4.46B | 4.28B | 4.56B | 5.29B |
| Total Liabilities | 553M | 1.02B | 315M | 168M | 587M | 1.11B | 1.88B | 2.72B | 3.99B | 4.24B |
| Shareholders' Equity | 83.4M | -141M | 757M | 1.47B | 1.01B | 3.52B | 2.58B | 1.57B | 350M | 873M |
| Cash & Short-term Investments | 69.4M | 27.3M | 40.8M | 548M | 96.5M | 2.55B | 1.67B | 1.20B | 1.53B | 2.23B |
| Total Debt | - | - | - | 50.0M | 335M | 774M | 1.26B | 2.07B | 2.97B | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -94.4M | -156M | -354M | -515M | -422M | -719M | -780M | -956M | -289M | - |
| Capital Expenditure | 169M | 225M | 185M | 131M | 218M | 545M | 500M | 330M | 158M | 123M |
| Free Cash Flow | -264M | -380M | -540M | -646M | -640M | -1.26B | -1.28B | -1.29B | -447M | -1.14B |
| Ratios | ||||||||||
| ROE | -123.2% | - | -122.6% | -43.7% | -76.1% | -27.2% | -40.8% | -66.5% | -277.6% | -119.5% |
| ROA | -16.1% | -25.3% | -86.5% | -39.2% | -48.2% | -20.7% | -23.6% | -24.4% | -21.3% | -19.7% |
| Net Profit Margin | -2,231.9% | -602.6% | -3,153.3% | -12,118.5% | -4,742.9% | -3,445.0% | -824.1% | -522.5% | -146.4% | -166.9% |
| Debt to Equity | - | - | - | 0.03x | 0.33x | 0.22x | 0.49x | 1.32x | 8.50x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mabwell (Shanghai) Bioscience Co. Ltd. A dividends
- Dividend yield
- 0.81%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 78.4M | 0.20 | - |
| 2024 | CNY 66.1M | 0.17 | - |
| 2023 | CNY 34.1M | 0.09 | - |
| 2022 | CNY 13.1M | 0.03 | - |
| 2021 | CNY 789K | 0.00 | - |
| 2020 | CNY 1.04M | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Mabwell (Shanghai) Bioscience Co. Ltd. A
- Insiders 50.57%
- Institutions 8.14%
- Public & others 41.29%
- Shares outstanding 400M
- Free float 248M
Mabwell (Shanghai) Bioscience Co. Ltd. A company profile
- Company name
- Mabwell (Shanghai) Bioscience Co. Ltd. A
- Ticker
- 688062.SHG
- ISIN
- CNE100005RD2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,325
- Fiscal year end
- December
- Address
- Building 2, Shanghai, China, 201210
- Phone
- 86 21 5833 2260
- Website
- mabwell.com
About Mabwell (Shanghai) Bioscience Co. Ltd. A
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
Mabwell (Shanghai) Bioscience Co. Ltd. A management
10- Dr. Datao Liu Ph.D.Chairman, CEO & GM · born 1972
- Mr. Jun HuaVP, CFO, Deputy GM & Executive Director · born 1981
- Dr. Xin Du Ph.D.Chief Scientific Officer & President of Maiwei (US) · born 1972
- Dr. Yinhan Guo Ph.D.Chief Research & Development Officer · born 1971
- Mr. Chunshan TangExecutive Director · born 1969
- Mr. Shu Hai Wang Ph.D.Deputy GM & Chief Medical Officer · born 1974
- Dr. Hai Wu Ph.D.Deputy GM, President of R&D and Director · born 1973
- Dr. Xun GuiVP, Deputy GM & Director · born 1986
- Mr. Jinchao ZhangDeputy General Manager · born 1972
- Ms. Kwan Wai LeungJoint Company Secretary · born 1983